New study tests if adding a second drug boosts UC treatment

This study looks at whether using two drugs together (upadacitinib and vedolizumab) works better than just one drug (upadacitinib alone) for people with moderate-to-severe ulcerative colitis, a chronic bowel disease. Researchers will review medical records from 150 adults across six hospitals in China to see which approach leads to more symptom relief and fewer side effects during the first 8 weeks of treatment. The goal is to provide real-world evidence to help doctors choose the best treatment plan.